Formulation and Evaluation of Solid Dispersion Incorporated Fast Disintegrating Tablets of Tenoxicam Using Design of Experiment

Mohammadi, Hafsa; Kumar, V Hemanath

doi:10.25004/ijpsdr.2019.110106

Cited by 7 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Characterization and evaluation of solid dispersions:Measurements of particle size and flow characteristics, such as angle of repose and Carr's index, were used to describe the solid dispersions made using different techniques. The surface properties, drug-excipient interactions and crystal shape of optimised solid dispersions were assessed by SEM analysis, DSC, and XRD analysis, respectively [10][11][12] .…”

Section: Physical Mixing Methodmentioning

confidence: 99%

Formulation and Evaluation of Lurasidone Hydrochloride Fast Dissolving Tablets

Hemalatha,

Ramu,

Vidyadhara

2023

JSFS

View full text Add to dashboard Cite

Antipsychotic medication lurasidone is used to treat schizophrenia and bipolar disorder. In this study, a new effort was made to improve the solubility, rate of dissolution, and oral bioavailability of the poorly soluble drug lurasidone by manufacturing it as solid dispersions utilising a variety of methods and a carrier called polyethylene glycol (PEG) 6000. The prepared solid dispersions were used to prepare fast dissolving tablets by using super disintegrants. A novel super disintegrant called Microcrystalline Cellulose-Polyethylene Glycol (MCC-PEG) Conjugate was also created as part of the project. PEGylation of Microcrystalline Cellulose (MCC) was done since PEG has the ability to increase the water absorption capacity and MCC acts as a disintegrant. Super disintegrants such as sodium starch glycolate, croscarmellose sodium, crospovidone, and microcrystalline cellulose (MCC)-polyethylene glycol (PEG) conjugate were used to create Lurasidone tablets that dissolve quickly. Tablets were tested for physical parameters and drug release by in vitro dissolution studies. Through SEM examination, DSC, and XRD tests, optimised solid dispersions surface properties, drug-excipient interactions, and crystal morphology have all been assessed. All the tablet preparations containing superdisintegrants were formed to release the drug in the order MCC-PEG Conjugate>Crospovidone> Croscarmellose sodium > Sodium starch glycolate. The dissolution rate of such tablet formulations were found to release the drug at a faster rate than the tablets prepared with plain drug.

show abstract

Section: Physical Mixing Methodmentioning

confidence: 99%

Formulation and Evaluation of Lurasidone Hydrochloride Fast Dissolving Tablets

Hemalatha,

Ramu,

Vidyadhara

2023

JSFS

View full text Add to dashboard Cite

show abstract

“…[7] Evaluation of Lovastatin SDs Solubility studies of lovastatin SD performed as per the published method. [8] The percentage practical yield [9] and % drug content [10,11] were evaluated as per the referred methods. The dispersions are further characterized for FTIR spectroscopic analysis, [12] XRD, [13,14] and SEM studies [15] for drug compatibility studies.…”

Section: Preliminary Solubility Studies Of Lovastatinmentioning

confidence: 99%

Design and Evaluation of Lovastatin Solid Dispersions Incorporated Trilayer Matrix Tablets

Priya

Reddy

2020

Int. J. Pharm. Sci. Drug Res.

View full text Add to dashboard Cite

The current work is aimed to design, prepare and evaluate the trilayer matrix tablets incorporated with lovastatin solid dispersion (SD) for extend drug release. The lovastatin SD prepared by using solvent evaporation technique with varying amounts of polymers (GMS II, Soluplus, Kolliphor ELP, PEG 2000 and Urea) for enhancing the drug solubility. All the formulations examined for physicochemical parameters are within the permissible limits. The optimized SD formulation was incorporated into trilayer matrix tablets which were prepared using different polymers (HPMC 15M & K100M, Chitosan, xanthan gum) by direct compression method for sustaining the drug release. The drug dissolution of optimized lovastatin SD formulation SD15 (drug, soluplus and SLN) was 99.88±5.32% within 60 min which is higher than pure drug 47.33±2.25% and other formulations. The FT-IR, XRD and SEM data assure the compatibility of drug and excipients and amorphous nature of lovastatin. The solid dispersions were further incorporated in to trilayer matrix tablets with active layer and barrier layers. Eight formulations of lovastatin trilayer matrix tablets (AF9-HF9) designed and checked for pre compression parameters. Formulation GF9 demonstrated highest drug release of 99.41±5.28% for 24 hours sustainably over an extended period of time and excellent flow properties. The release order kinetics data indicate the zero order release with highest R2 of 0.9957 for GF9, superior than market extended release formulation (R2=0.9934). All the formulations showed best fit to Higuchi model and Korsmeyer-Peppa’s model indicating diffusion and non-Fickian diffusion process of drug release. GF90 was found to be stable for 180 days at accelerated conditions. Hence the solubility, dissolution rate of lovastatin was enhanced by SD technique further incorporated in to trilayer matrix tablets for sustainable extended drug release upto 24 h.

show abstract

“…[10] Evaluation of CPG SDS The solubility study of CPG SD performed as per published method by Higuchi and Connors in 1965. [11] The percentage practical yield, [12] % drug content, [13] and in vitro drug dissolution study [14] were evaluated as per the referred methods. The SD is further characterized for FTIR analysis, [15] X-ray diffractometer (XRD), [16,17] and SEM studies [18] for drug compatibility studies.…”

Section: Preliminary Solubility Study Of Cpgmentioning

confidence: 99%

Enhancement of Solubility And Dissolution Profile of Clopidogrel By Various Solid Dispersion Formulations

Khader

Salfi

2020

Int. J. Pharm. Sci. Drug Res.

View full text Add to dashboard Cite

The present research is aimed at enhancing solubility and drug dissolution of clopidogrel (CPG) used as oral antiplatelet agent by employing solid dispersion (SD) technique. Total 40 SDs formulated with drug: polymers (pluronic F127, poloxamer 407, labrafil PG, PEG 6000, gelucire 50/13), in varying ratios (1:0.5, 1:1, 1:2, 1:3, 1:4) of which CPG1 to CPG20 and CPG21 to CPG40 prepared by adopting solvent evaporation method fusion (melt) method respectively. The formulation CPG40 containing pluronic F127 as polymer showed highest solubility of 6.57±0.04 mg/ml) that is 45 folds than pure drug. Similar results reflected in the dissolution studies where CPG40 containing CPG: pluronic F127 in 1:4 ratio showed maximum % drug content, % practical yield and drug dissolution of 99.14% in 60 minutes when compared with other formulations and pure drug (32.76%) obtained by fusion melt method. From FTIR studies the optimized formulation CPG40 showed the compatibility between drug and polymers. XRD and SEM studies showed CPG40 exists in amorphous form that fetched in better drug release from the SD formulation in comparison to pure drug.

show abstract

Formulation and Evaluation of Solid Dispersion Incorporated Fast Disintegrating Tablets of Tenoxicam Using Design of Experiment

Cited by 7 publications

References 11 publications

Formulation and Evaluation of Lurasidone Hydrochloride Fast Dissolving Tablets

Formulation and Evaluation of Lurasidone Hydrochloride Fast Dissolving Tablets

Design and Evaluation of Lovastatin Solid Dispersions Incorporated Trilayer Matrix Tablets

Enhancement of Solubility And Dissolution Profile of Clopidogrel By Various Solid Dispersion Formulations

Contact Info

Product

Resources

About